Liquidia wins dismissal of UTHR cross-claim over YUTREPIA PH-ILD label; FDA approval path cleared

Liquidia Corp

District Court dismissed UTHR's cross-claim without prejudice for lack of standing and ripeness.
FDA can grant final YUTREPIA approval after regulatory exclusivity expires on May 23, 2025.
PDUFA goal date for YUTREPIA NDA remains May 24, 2025.
UTHR retains the right to appeal the court's ruling.
CEO cites court decision as validating FDA's acceptance of PH-ILD indication in NDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.